Buckley NE - Search Results

1

Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells.

El-Tanani MK, Yuen HF, Shi Z, Platt-Higgins A, Buckley NE, Mullan PB, Harkin DP, Johnston PG, Rudland PS. El-Tanani MK, et al. Among authors: buckley ne. Cancer Sci. 2010 Jun;101(6):1354-60. doi: 10.1111/j.1349-7006.2010.01561.x. Epub 2010 Mar 10. Cancer Sci. 2010. PMID: 20384635 Free PMC article.

2

The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1- and interferon-gamma-mediated apoptosis.

Mullan PB, Hosey AM, Buckley NE, Quinn JE, Kennedy RD, Johnston PG, Harkin DP. Mullan PB, et al. Among authors: buckley ne. Oncogene. 2005 Aug 18;24(35):5492-501. doi: 10.1038/sj.onc.1208698. Oncogene. 2005. PMID: 15940267

3

BRCA1 regulates IFN-gamma signaling through a mechanism involving the type I IFNs.

Buckley NE, Hosey AM, Gorski JJ, Purcell JW, Mulligan JM, Harkin DP, Mullan PB. Buckley NE, et al. Mol Cancer Res. 2007 Mar;5(3):261-70. doi: 10.1158/1541-7786.MCR-06-0250. Mol Cancer Res. 2007. PMID: 17374731

4

BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer.

Gorski JJ, James CR, Quinn JE, Stewart GE, Staunton KC, Buckley NE, McDyer FA, Kennedy RD, Wilson RH, Mullan PB, Harkin DP. Gorski JJ, et al. Among authors: buckley ne. Breast Cancer Res Treat. 2010 Aug;122(3):721-31. doi: 10.1007/s10549-009-0565-0. Epub 2009 Oct 31. Breast Cancer Res Treat. 2010. PMID: 19882246

5

T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells.

Redmond KL, Crawford NT, Farmer H, D'Costa ZC, O'Brien GJ, Buckley NE, Kennedy RD, Johnston PG, Harkin DP, Mullan PB. Redmond KL, et al. Among authors: buckley ne. Oncogene. 2010 Jun 3;29(22):3252-62. doi: 10.1038/onc.2010.84. Epub 2010 Mar 29. Oncogene. 2010. PMID: 20348948

6

The DeltaNp63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer.

Buckley NE, Conlon SJ, Jirstrom K, Kay EW, Crawford NT, O'Grady A, Sheehan K, Mc Dade SS, Wang CW, McCance DJ, Johnston PG, Kennedy RD, Harkin DP, Mullan PB. Buckley NE, et al. Cancer Res. 2011 Mar 1;71(5):1933-44. doi: 10.1158/0008-5472.CAN-10-2717. Cancer Res. 2011. PMID: 21363924

7

BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.

Tkocz D, Crawford NT, Buckley NE, Berry FB, Kennedy RD, Gorski JJ, Harkin DP, Mullan PB. Tkocz D, et al. Among authors: buckley ne. Oncogene. 2012 Aug 9;31(32):3667-78. doi: 10.1038/onc.2011.531. Epub 2011 Nov 28. Oncogene. 2012. PMID: 22120723

8

BRCA1--conductor of the breast stem cell orchestra: the role of BRCA1 in mammary gland development and identification of cell of origin of BRCA1 mutant breast cancer.

Buckley NE, Mullan PB. Buckley NE, et al. Stem Cell Rev Rep. 2012 Sep;8(3):982-93. doi: 10.1007/s12015-012-9354-y. Stem Cell Rev Rep. 2012. PMID: 22426855 Review.

9

BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers.

Buckley NE, Nic An tSaoir CB, Blayney JK, Oram LC, Crawford NT, D'Costa ZC, Quinn JE, Kennedy RD, Harkin DP, Mullan PB. Buckley NE, et al. Nucleic Acids Res. 2013 Oct;41(18):8601-14. doi: 10.1093/nar/gkt626. Epub 2013 Jul 17. Nucleic Acids Res. 2013. PMID: 23863842 Free PMC article.

10

S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability.

Buckley NE, D'Costa Z, Kaminska M, Mullan PB. Buckley NE, et al. Cell Death Dis. 2014 Feb 20;5(2):e1070. doi: 10.1038/cddis.2014.31. Cell Death Dis. 2014. PMID: 24556685 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

68 results

Search Page

Filters